Timely biomarker testing is essential for accurate cancer diagnoses and effective treatment. We are evaluating how the Medicare 14-Day Rule affects timely testing, treatment decisions, and billing processes.LUNGevity, the Academy of Oncology Nurse & Patient Navigators (AONN+), the Association of Cancer Care Centers (ACCC), and the Advanced Practitioner Society for Hematology and Oncology (APSHO) are conducting a nationwide survey to assess its impact on patient care across all cancers, as well as its billing implications for hospitals and health systems.We are seeking input from healthcare providers, billing professionals, and practice managers. Your participation will help drive advocacy efforts to improve access to precision medicine.[url] sw2.decipherinc.com/survey/selfserve/1ce2/250403?list=2 [/url]The survey will be available for a limited time. As a thank you, the first 300 complete survey responses have an option to receive a $20 Starbucks gift card.For questions, please contact Nikki Martin at nmartin@lungevity.org.Thank you for advancing biomarker testing and cancer care!